Terms ending in 2039
Every in-force patent on Gilead Sciences, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,253,524 | Metabolites of Bictegravir In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 10,710,986 | PD-1/PD-L1 Inhibitors In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 11,555,029 | PD-1/PD-L1 Inhibitors In force · Medium confidence | Gilead Sciences, Inc. | In force | Medium confidence | |
| US 12,338,233 | PD-1/PD-L1 Inhibitors In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 10,836,746 | Therapeutic Compounds In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 11,267,801 | Therapeutic Compounds In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 11,753,399 | Therapeutic Compounds In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 10,696,657 | Methods and Intermediates for Preparing Therapeutic Compounds In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 11,117,886 | Methods and Intermediates for Preparing Therapeutic Compounds In force · Medium confidence | Gilead Sciences, Inc. | In force | Medium confidence | |
| US 12,122,765 | Methods and Intermediates for Preparing Therapeutic Compounds In force · Medium confidence | Gilead Sciences, Inc. | In force | Medium confidence | |
| 42 more term ends in 2039 · Pro | |||||
10 of 52 patents shown. Soonest term end first, then patent number.
Pro members see all 52.
50 of these are in force and held by Gilead Sciences, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.